drugset / Trial / NCT01105312

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT01105312

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of panobinostat when given together with letrozole and to see how well it works in treating patients with metastatic breast cancer.

Timeline

Start
2010-09
Primary completion
2013-08
Completion
2013-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Panobinostat Small molecule 20 mg Oral
Subject Panobinostat Small molecule 30 mg Oral

Indications